GSK plc (GSK) is focused on research, development and manufacturing of novel pharmaceutical medicines, vaccines and consumer healthcare products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

GSK’s R&D activities are focused on developing new and improved vaccines, prophylactic and therapeutic vaccines related to several therapeutic areas including respiratory, cancer, HIV, immuno-inflammation, infectious diseases and other diseases. Its consumer healthcare research focuses on five major categories: Pain Relief, Respiratory, Oral Health, Skin Health, and Nutrition and Gastrointestinal. In FY2022, the company spent GBP5,062 million on R&D. It has major research centers in the UK, the US, Canada, Asia (Singapore and China) and Europe (Spain, Belgium and Germany). GSK has partnerships (pharmaceuticals) with academic institutions, public-private partnerships, pharmaceutical companies and biotechnology companies; and external scientific partnerships (vaccines) with scientists and leading academic and public health institutions. Owns numerous domestic and foreign patents cover pharmaceutical and vaccine products and their uses, product manufacturing processes and pharmaceutical formulations. As of FY2022, the company’s pipeline consisted of 22 vaccines and 47 medicines under development. The company developed products in the field of infectious diseases, HIV, immunology/respiratory and oncology. It’s major product developments are ARESVI-006 for RSV and Shingles, Xevudy (sotrovimab)for the treatment of Covid-19, Bepirovirsen for Chronic hepatitis B in the field of infectious diseases; Cabenuva, Tivicay and Triumeq in the field of HIV, Benlysta for the treatment of systemic lupus erythematosus (SLE) and Nucala (mepolizumab) for eosinophil-driven diseases in the field of immunology/respiratory; and Jemperli, Zejula and Blenrep for the treatment of different kind of cancers in the field of oncology.